The corporations related to pharmaceuticals and medical devices, WSI, announced on the 8th that it has secured exclusive sales rights for the pulmonary edema testing device 'ReDs' after entering into a strategic partnership agreement with Mitrassist, located in Shanghai, China.
According to WSI, Mitrassist is a corporation that acquired Sensible Medical, which developed the ReDs, a pulmonary edema testing device that applies Israeli military radar technology.
ReDs is a device that measures the distribution of residual pulmonary edema using radar technology, unlike X-rays or computed tomography (CT), providing accurate figures, and has obtained both U.S. FDA and European CE certifications.
Among pulmonary edema, cardiogenic pulmonary edema, caused by heart disease, occurs due to increased pulmonary vein hydrostatic pressure resulting from heart failure. WSI expects this will assist in the corporation's growth as it expands into the cardiovascular institutional sector.
A WSI official noted, 'By adding ReDs to our cardiovascular business currently under intensive development, we expect to expand our business portfolio and increase revenue.'
Mitrassist is known as a corporation that secured a $16 million investment from China's leading Ping An Group, which recognized its technological capabilities and growth potential. The two sides plan to promote extensive cooperation in cardiovascular product development through this agreement.